Use of Biomarkers in the Evaluation and Treatment of Hypertensive Patients

Overview

Journal Curr Hypertens Rep

Specialty Cardiology & Vascular Diseases

Date 2016 May 26

PMID 27221728

Citations 6

Authors

Gemma Currie

Christian Delles

Affiliations

Soon will be listed here.

Abstract

The current definition of hypertension is based on blood pressure values, and blood pressure also drives treatment decisions, is the most important treatment monitoring tool and helps estimating risk of hypertension-related organ damage. In an era of precision medicine, additional biomarkers are needed in the diagnosis and management of patients with hypertension. In this review, we outline the areas in which functional, imaging and circulating biomarkers could help in a more individualised definition of hypertension and associated risk. We will cover biomarkers for diagnosis; of pathophysiology and prediction of hypertension; response to treatment, organ damage; and to monitor treatment. A clear focus is on the vasculature, the heart and the kidneys, whereas we see a need to further develop biomarkers of cerebral function in order to diagnose cognition deficits and monitor changes in cognition in the future to support addressing the growing burden of hypertension-associated vascular dementia.

Citing Articles

The Future of Precision Medicine in the Cure of Alzheimer's Disease.

Arafah A, Khatoon S, Rasool I, Khan A, Rather M, Abujabal K Biomedicines. 2023; 11(2).

PMID: 36830872 PMC: 9953731. DOI: 10.3390/biomedicines11020335.

A Precision Medicine Approach to Treating Alzheimer's Disease Using Rosiglitazone Therapy: A Biomarker Analysis of the REFLECT Trials.

OBryant S, Zhang F, Petersen M, Johnson L, Hall J, Rissman R J Alzheimers Dis. 2021; 81(2):557-568.

PMID: 33814447 PMC: 8203239. DOI: 10.3233/JAD-201610.

Parameters of Central Hemodynamics as New Biomarkers of Cardiovascular Risk.

Vilela-Martin J Arq Bras Cardiol. 2021; 115(6):1133-1134.

PMID: 33470312 PMC: 8133714. DOI: 10.36660/abc.20201218.

Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome.

Petersen M, Rafii M, Zhang F, Hall J, Julovich D, Ances B J Alzheimers Dis. 2020; 79(2):671-681.

PMID: 33337378 PMC: 8273927. DOI: 10.3233/JAD-201167.

Personalized medicine-a modern approach for the diagnosis and management of hypertension.

Savoia C, Volpe M, Grassi G, Borghi C, Agabiti Rosei E, Touyz R Clin Sci (Lond). 2017; 131(22):2671-2685.

PMID: 29109301 PMC: 5736921. DOI: 10.1042/CS20160407.

References

Okin P, Devereux R, Jern S, Kjeldsen S, Julius S, Nieminen M . Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004; 292(19):2343-9. DOI: 10.1001/jama.292.19.2343. View

Tinetti M, Han L, Lee D, McAvay G, Peduzzi P, Gross C . Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med. 2014; 174(4):588-95. PMC: 4136657. DOI: 10.1001/jamainternmed.2013.14764. View

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

Luders S, Schrader J, Berger J, Unger T, Zidek W, Bohm M . The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008; 26(7):1487-96. DOI: 10.1097/HJH.0b013e3282ff8864. View

Kitagawa K . Cerebral blood flow measurement by PET in hypertensive subjects as a marker of cognitive decline. J Alzheimers Dis. 2010; 20(3):855-9. DOI: 10.3233/JAD-2010-091324. View

Mandel E, Forman J, Curhan G, Taylor E . Plasma bicarbonate and odds of incident hypertension. Am J Hypertens. 2013; 26(12):1405-12. PMC: 3816626. DOI: 10.1093/ajh/hpt133. View

Hage F . C-reactive protein and hypertension. J Hum Hypertens. 2013; 28(7):410-5. DOI: 10.1038/jhh.2013.111. View

Harazny J, Ritt M, Baleanu D, Ott C, Heckmann J, Schlaich M . Increased wall:lumen ratio of retinal arterioles in male patients with a history of a cerebrovascular event. Hypertension. 2007; 50(4):623-9. DOI: 10.1161/HYPERTENSIONAHA.107.090779. View

Kearney P, Whelton M, Reynolds K, Muntner P, Whelton P, He J . Global burden of hypertension: analysis of worldwide data. Lancet. 2005; 365(9455):217-23. DOI: 10.1016/S0140-6736(05)17741-1. View

10.

Julius S, Nesbitt S, Egan B, Weber M, Michelson E, Kaciroti N . Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006; 354(16):1685-97. DOI: 10.1056/NEJMoa060838. View

11.

Shlipak M, Matsushita K, Arnlov J, Inker L, Katz R, Polkinghorne K . Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013; 369(10):932-43. PMC: 3993094. DOI: 10.1056/NEJMoa1214234. View

12.

Kherada N, Heimowitz T, Rosendorff C . Antihypertensive Therapies and Cognitive Function: a Review. Curr Hypertens Rep. 2015; 17(10):79. DOI: 10.1007/s11906-015-0592-7. View

13.

Menni C, Graham D, Kastenmuller G, Alharbi N, Alsanosi S, McBride M . Metabolomic identification of a novel pathway of blood pressure regulation involving hexadecanedioate. Hypertension. 2015; 66(2):422-9. PMC: 4490909. DOI: 10.1161/HYPERTENSIONAHA.115.05544. View

14.

Wang T, Gona P, Larson M, Levy D, Benjamin E, Tofler G . Multiple biomarkers and the risk of incident hypertension. Hypertension. 2007; 49(3):432-8. DOI: 10.1161/01.HYP.0000256956.61872.aa. View

15.

Williams B, MacDonald T, Morant S, Webb D, Sever P, McInnes G . Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015; 386(10008):2059-2068. PMC: 4655321. DOI: 10.1016/S0140-6736(15)00257-3. View

16.

Herbert A, Cruickshank J, Laurent S, Boutouyrie P . Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. Eur Heart J. 2014; 35(44):3122-33. DOI: 10.1093/eurheartj/ehu293. View

17.

Pase M, Himali J, Mitchell G, Beiser A, Maillard P, Tsao C . Association of Aortic Stiffness With Cognition and Brain Aging in Young and Middle-Aged Adults: The Framingham Third Generation Cohort Study. Hypertension. 2016; 67(3):513-9. PMC: 4752398. DOI: 10.1161/HYPERTENSIONAHA.115.06610. View

18.

Titze J . Sodium balance is not just a renal affair. Curr Opin Nephrol Hypertens. 2014; 23(2):101-5. PMC: 4932095. DOI: 10.1097/01.mnh.0000441151.55320.c3. View

19.

Zoccali C, Mallamaci F . Uric acid, hypertension, and cardiovascular and renal complications. Curr Hypertens Rep. 2013; 15(6):531-7. DOI: 10.1007/s11906-013-0391-y. View

20.

Kunutsor S, Apekey T, Steur M . Vitamin D and risk of future hypertension: meta-analysis of 283,537 participants. Eur J Epidemiol. 2013; 28(3):205-21. DOI: 10.1007/s10654-013-9790-2. View